Characterised Viable Autologous Cartilage Cells Expanded Ex Vivo Expressing Specific Marker Proteins

Summary

Characterised Viable Autologous Cartilage Cells Expanded Ex Vivo Expressing Specific Marker Proteins (CHEMBL6068345) is an approved cell; indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Cell
• Indications: 1 condition
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068345
Name	Characterised Viable Autologous Cartilage Cells Expanded Ex Vivo Expressing Specific Marker Proteins
Type	Cell
Max phase	4

Also known as: Chondrocelect

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00414700	PHASE3	COMPLETED	RCT of ChondroCelect® (in an ACI Procedure) vs Microfracture in the Repair of Cartilage Defects of the Knee

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).